Riskpilot← Back to searchSign inGet full accessMundipharma AB
ABActiveOrg 5565546198Mölndalsvägen 30 BWholesale of pharmaceutical and medical goods · NACE 4646Est. 19981 employees
Revenue 2024
SEK 95,7M
-10% vs 2023
EBITDA margin
4.2%
+77% vs 2023
Equity ratio
50.1%
Financial strength
Net profit 2024
SEK 3,8M
+4981% vs 2023
| Revenue | SEK 95,7M | -10% |
| EBITDA | SEK 4M | +77% |
| Net profit | SEK 3,8M | +4981% |
| Total assets | SEK 124,6M | +21% |
| Equity | SEK 62,4M | -23% |
| Employees | 1 | — |
Legal name
Mundipharma AB
Org number
5565546198
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
30 mars 1998
Share capital
SEK 150 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget har till föremål för sin verksamhet att självt och/eller genom hel- eller delägda dotterbolag bedriva verksamhet företrädesvis inom forskning och utveckling, tillverkning, registrering, marknadsföring, distribution försäljning, import och export av farmaceutiska produkter, läkemedel, kemikalier, toalettartiklar och kosmetika samt därmed förenlig verksamhet.
Address
Mölndalsvägen 30 B
Phone
+46317737530
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 128 115 | 101 780 | 97 166 | 106 444 | 95 743 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 4 026 | 3 026 | 3 044 | 2 268 | 4 021 |
| Depreciation & amort. | −52 | −13 | −13 | −5 | −0 |
| EBIT | 3 974 | 3 013 | 3 031 | 2 263 | 4 021 |
| Net financials | −285 | 60 | −630 | −683 | −211 |
| Profit before tax | 3 894 | 3 096 | 2 401 | 1 892 | 3 956 |
| Tax | −1 073 | −1 218 | −1 766 | −1 817 | −145 |
| Net profit | 2 821 | 1 878 | 635 | 75 | 3 811 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 101 745 | 136 075 | 143 394 | 103 153 | 124 603 |
| Equity | 80 057 | 80 840 | 81 476 | 81 551 | 62 391 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 21 688 | 55 235 | 61 918 | 21 602 | 62 212 |
| Total debt | 21 688 | 55 235 | 61 918 | 21 602 | 62 212 |
EBITDA margin
4.2%
This company
15.8%
Market median
-73% vs market
20202024
Equity ratio
50.1%
This company
38.2%
Market median
+31% vs market
20202024
Return on equity
6.1%
This company
18.4%
Market median
-67% vs market
20202024
Net profit margin
4.0%
This company
8.1%
Market median
-51% vs market
20202024
Asset turnover
0.77×
This company
1.12×
Market median
-31% vs market
20202024
Debt / equity
1.00×
This company
0.62×
Market median
-61% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
OP Authorized Recipient of Service | Authorized Recipient of Service | 2025 |
GK Chief Auditor | Chief Auditor | 2024 |
| Former (5) | ||
JM Chief Executive Officer | Chief Executive Officer | 2022 – 2023 |
BA Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2021 – 2022 |
KK Chief Executive Officer | Chief Executive Officer | 2020 – 2021 |
NB Chief Auditor | Chief Auditor | 2020 – 2023 |
JG Authorized Recipient of Service | Authorized Recipient of Service | 2020 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Chairman | 2021 | |
| Board of Directors | 2024 | |
| Former (7) | ||
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2020 – 2022 | |
| Chairman | 2020 – 2021 | |
| Deputy Board Member | 2020 – 2021 | |
| Board of Directors | 2022 – 2022 | |
| Board of Directors | 2020 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Mundipharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jennie Maria Synnöve Tjernström | Chief Executive Officer | 0 companies |
| O P Joakim Abrahamsson Zetterström | Authorized Recipient of Service | 0 companies |
| Björn Andreas Hanning | Deputy Chief Executive Officer | 0 companies |
| Gustav Karl Emil Johansson | Chief Auditor | 0 companies |
| Kjetil Kollstad | Chief Executive Officer | 0 companies |
| Nina Birgit Brohall | Chief Auditor | 0 companies |
| Johanna Gunilla Maria Wärnberg | Authorized Recipient of Service | 0 companies |
| Hywel Rhys Day | Board of Directors | 0 companies |
| Graham Hodge | Board of Directors | 0 companies |
| Marian Morrinson | Board of Directors | 0 companies |
| Stephen Johan Jamieson | Chairman | 0 companies |
| Salvador Lopez Orland | Board of Directors | 0 companies |
| Stuart D Baker | Chairman | 0 companies |
| Gareth Kendall | Deputy Board Member | 0 companies |
| Petrus Jacobus Verwaijen | Board of Directors | 0 companies |
| Lisbeth Kattenhoj | Board of Directors | 0 companies |
| Floris Anne Everard Bongenaar | Board of Directors | 0 companies |